Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics

A randomized, 6-week, open-label study

Joseph Patrick McEvoy, Leslie Citrome, David Hernandez, Josephine Cucchiaro, Jay Hsu, Andrei Pikalov, Antony Loebel

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Objective: To examine the effectiveness of switching patients to lurasidone using 3 different dosing strategies. Method: Adults with DSM-IV-defined schizophrenia or schizoaffective disorder in a nonacute phase of illness were randomized to 1 of 3 lurasidone dosing regimens for the initial 2 weeks of the study: (1) 40 mg/d for 2 weeks; (2) 40 mg/d for 1 week, increased to 80 mg/d on day 8 for week 2 (up-titration group); and (3) 80 mg/d for 2 weeks. Lurasidone was then flexibly dosed (40-120 mg/d) for the subsequent 4 weeks of the study. The preswitch antipsychotic agent was tapered by day 7 to 50% of the original dose and discontinued by the end of week 2. Subjects were stratified on the basis of whether the primary preswitch antipsychotic medication was classified as "sedating" (olanzapine or quetiapine) or "nonsedating" (all other antipsychotics). The primary outcome measure was time to treatment failure, defined as any occurrence of insufficient clinical response, exacerbation of underlying disease, or discontinuation due to an adverse event. The study was conducted from June 2010 to May 2011. Results: Of 240 subjects treated in this study, 86 (35.8%) were treated with an antecedent sedating antipsychotic, and 154 (64.2%) were treated with an antecedent nonsedating antipsychotic. Nineteen (7.9%) of the 240 patients experienced treatment failure. No clinically relevant differences were observed when the 3 randomized switch groups were compared. Treatment failure rates were 10/86 (11.6%) versus 9/154 (5.8%) among subjects who had been receiving a preswitch sedating versus nonsedating antipsychotic medication, respectively. Consistent with prior studies of lurasidone, there was no signal for clinically relevant adverse changes in body weight, glucose, insulin, lipids, or prolactin; mean improvements in weight and lipids were observed. Movement disorder rating scales did not demonstrate meaningful changes. The incidence of akathisia as an adverse event was 12.5%; only 1 subject (0.4%) discontinued due to akathisia. Conclusions: Switching patients to lurasidone can be successfully accomplished by starting at 40 mg/d for 2 weeks, or 80 mg/d for 2 weeks, or 40 mg/d for 1 week followed by 80 mg/d the second week.

Original languageEnglish (US)
Pages (from-to)170-179
Number of pages10
JournalJournal of Clinical Psychiatry
Volume74
Issue number2
DOIs
StatePublished - Jan 1 2013
Externally publishedYes

Fingerprint

Psychotic Disorders
Antipsychotic Agents
Schizophrenia
Treatment Failure
Psychomotor Agitation
olanzapine
Lipids
Body Weight Changes
Movement Disorders
Diagnostic and Statistical Manual of Mental Disorders
Prolactin
Disease Progression
Lurasidone Hydrochloride
Outcome Assessment (Health Care)
Insulin
Weights and Measures
Glucose
Incidence

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics : A randomized, 6-week, open-label study. / McEvoy, Joseph Patrick; Citrome, Leslie; Hernandez, David; Cucchiaro, Josephine; Hsu, Jay; Pikalov, Andrei; Loebel, Antony.

In: Journal of Clinical Psychiatry, Vol. 74, No. 2, 01.01.2013, p. 170-179.

Research output: Contribution to journalArticle

McEvoy, Joseph Patrick ; Citrome, Leslie ; Hernandez, David ; Cucchiaro, Josephine ; Hsu, Jay ; Pikalov, Andrei ; Loebel, Antony. / Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics : A randomized, 6-week, open-label study. In: Journal of Clinical Psychiatry. 2013 ; Vol. 74, No. 2. pp. 170-179.
@article{ef1d1d6dfdde4618a232d15bd171d757,
title = "Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: A randomized, 6-week, open-label study",
abstract = "Objective: To examine the effectiveness of switching patients to lurasidone using 3 different dosing strategies. Method: Adults with DSM-IV-defined schizophrenia or schizoaffective disorder in a nonacute phase of illness were randomized to 1 of 3 lurasidone dosing regimens for the initial 2 weeks of the study: (1) 40 mg/d for 2 weeks; (2) 40 mg/d for 1 week, increased to 80 mg/d on day 8 for week 2 (up-titration group); and (3) 80 mg/d for 2 weeks. Lurasidone was then flexibly dosed (40-120 mg/d) for the subsequent 4 weeks of the study. The preswitch antipsychotic agent was tapered by day 7 to 50{\%} of the original dose and discontinued by the end of week 2. Subjects were stratified on the basis of whether the primary preswitch antipsychotic medication was classified as {"}sedating{"} (olanzapine or quetiapine) or {"}nonsedating{"} (all other antipsychotics). The primary outcome measure was time to treatment failure, defined as any occurrence of insufficient clinical response, exacerbation of underlying disease, or discontinuation due to an adverse event. The study was conducted from June 2010 to May 2011. Results: Of 240 subjects treated in this study, 86 (35.8{\%}) were treated with an antecedent sedating antipsychotic, and 154 (64.2{\%}) were treated with an antecedent nonsedating antipsychotic. Nineteen (7.9{\%}) of the 240 patients experienced treatment failure. No clinically relevant differences were observed when the 3 randomized switch groups were compared. Treatment failure rates were 10/86 (11.6{\%}) versus 9/154 (5.8{\%}) among subjects who had been receiving a preswitch sedating versus nonsedating antipsychotic medication, respectively. Consistent with prior studies of lurasidone, there was no signal for clinically relevant adverse changes in body weight, glucose, insulin, lipids, or prolactin; mean improvements in weight and lipids were observed. Movement disorder rating scales did not demonstrate meaningful changes. The incidence of akathisia as an adverse event was 12.5{\%}; only 1 subject (0.4{\%}) discontinued due to akathisia. Conclusions: Switching patients to lurasidone can be successfully accomplished by starting at 40 mg/d for 2 weeks, or 80 mg/d for 2 weeks, or 40 mg/d for 1 week followed by 80 mg/d the second week.",
author = "McEvoy, {Joseph Patrick} and Leslie Citrome and David Hernandez and Josephine Cucchiaro and Jay Hsu and Andrei Pikalov and Antony Loebel",
year = "2013",
month = "1",
day = "1",
doi = "10.4088/JCP.12m07992",
language = "English (US)",
volume = "74",
pages = "170--179",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "2",

}

TY - JOUR

T1 - Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics

T2 - A randomized, 6-week, open-label study

AU - McEvoy, Joseph Patrick

AU - Citrome, Leslie

AU - Hernandez, David

AU - Cucchiaro, Josephine

AU - Hsu, Jay

AU - Pikalov, Andrei

AU - Loebel, Antony

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Objective: To examine the effectiveness of switching patients to lurasidone using 3 different dosing strategies. Method: Adults with DSM-IV-defined schizophrenia or schizoaffective disorder in a nonacute phase of illness were randomized to 1 of 3 lurasidone dosing regimens for the initial 2 weeks of the study: (1) 40 mg/d for 2 weeks; (2) 40 mg/d for 1 week, increased to 80 mg/d on day 8 for week 2 (up-titration group); and (3) 80 mg/d for 2 weeks. Lurasidone was then flexibly dosed (40-120 mg/d) for the subsequent 4 weeks of the study. The preswitch antipsychotic agent was tapered by day 7 to 50% of the original dose and discontinued by the end of week 2. Subjects were stratified on the basis of whether the primary preswitch antipsychotic medication was classified as "sedating" (olanzapine or quetiapine) or "nonsedating" (all other antipsychotics). The primary outcome measure was time to treatment failure, defined as any occurrence of insufficient clinical response, exacerbation of underlying disease, or discontinuation due to an adverse event. The study was conducted from June 2010 to May 2011. Results: Of 240 subjects treated in this study, 86 (35.8%) were treated with an antecedent sedating antipsychotic, and 154 (64.2%) were treated with an antecedent nonsedating antipsychotic. Nineteen (7.9%) of the 240 patients experienced treatment failure. No clinically relevant differences were observed when the 3 randomized switch groups were compared. Treatment failure rates were 10/86 (11.6%) versus 9/154 (5.8%) among subjects who had been receiving a preswitch sedating versus nonsedating antipsychotic medication, respectively. Consistent with prior studies of lurasidone, there was no signal for clinically relevant adverse changes in body weight, glucose, insulin, lipids, or prolactin; mean improvements in weight and lipids were observed. Movement disorder rating scales did not demonstrate meaningful changes. The incidence of akathisia as an adverse event was 12.5%; only 1 subject (0.4%) discontinued due to akathisia. Conclusions: Switching patients to lurasidone can be successfully accomplished by starting at 40 mg/d for 2 weeks, or 80 mg/d for 2 weeks, or 40 mg/d for 1 week followed by 80 mg/d the second week.

AB - Objective: To examine the effectiveness of switching patients to lurasidone using 3 different dosing strategies. Method: Adults with DSM-IV-defined schizophrenia or schizoaffective disorder in a nonacute phase of illness were randomized to 1 of 3 lurasidone dosing regimens for the initial 2 weeks of the study: (1) 40 mg/d for 2 weeks; (2) 40 mg/d for 1 week, increased to 80 mg/d on day 8 for week 2 (up-titration group); and (3) 80 mg/d for 2 weeks. Lurasidone was then flexibly dosed (40-120 mg/d) for the subsequent 4 weeks of the study. The preswitch antipsychotic agent was tapered by day 7 to 50% of the original dose and discontinued by the end of week 2. Subjects were stratified on the basis of whether the primary preswitch antipsychotic medication was classified as "sedating" (olanzapine or quetiapine) or "nonsedating" (all other antipsychotics). The primary outcome measure was time to treatment failure, defined as any occurrence of insufficient clinical response, exacerbation of underlying disease, or discontinuation due to an adverse event. The study was conducted from June 2010 to May 2011. Results: Of 240 subjects treated in this study, 86 (35.8%) were treated with an antecedent sedating antipsychotic, and 154 (64.2%) were treated with an antecedent nonsedating antipsychotic. Nineteen (7.9%) of the 240 patients experienced treatment failure. No clinically relevant differences were observed when the 3 randomized switch groups were compared. Treatment failure rates were 10/86 (11.6%) versus 9/154 (5.8%) among subjects who had been receiving a preswitch sedating versus nonsedating antipsychotic medication, respectively. Consistent with prior studies of lurasidone, there was no signal for clinically relevant adverse changes in body weight, glucose, insulin, lipids, or prolactin; mean improvements in weight and lipids were observed. Movement disorder rating scales did not demonstrate meaningful changes. The incidence of akathisia as an adverse event was 12.5%; only 1 subject (0.4%) discontinued due to akathisia. Conclusions: Switching patients to lurasidone can be successfully accomplished by starting at 40 mg/d for 2 weeks, or 80 mg/d for 2 weeks, or 40 mg/d for 1 week followed by 80 mg/d the second week.

UR - http://www.scopus.com/inward/record.url?scp=84874607585&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874607585&partnerID=8YFLogxK

U2 - 10.4088/JCP.12m07992

DO - 10.4088/JCP.12m07992

M3 - Article

VL - 74

SP - 170

EP - 179

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 2

ER -